Global Peanut Allergy Vaccine Market Size By Type (ASP0892, AR101), By Application (Hospitals, Personal Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Peanut Allergy Vaccine Market was valued at USD 360 million in 2023 and is projected to reach USD 1.06 billion by 2031, growing at a robust CAGR of 14.2% during the forecast period from 2023 to 2031. This market is gaining momentum due to the increasing prevalence of peanut allergies, especially among children, the rising awareness of food allergies, and growing R&D investments in immunotherapy-based treatments. The demand for effective, long-lasting peanut allergy treatments beyond avoidance strategies is accelerating the development and commercialization of vaccines aimed at desensitizing the immune system.

Drivers:

Rising Prevalence of Peanut Allergies:

Globally, peanut allergy is among the most common food allergies, particularly in North America and Europe. The growing incidence is driving demand for reliable vaccine solutions that offer long-term immunity or reduced sensitivity.

Increased Focus on Allergen Immunotherapy:

Allergen-specific immunotherapy has emerged as a key area of innovation in treating allergies. Companies are advancing novel vaccines and therapies to address the root cause of allergies rather than just managing symptoms.

Supportive Regulatory Environment:

Favorable regulations and accelerated approval pathways (such as orphan drug designation and fast-track status) for allergy vaccines are fostering product development and market entry.

Restraints:

High Development Costs and Long Approval Timelines:

Peanut allergy vaccines require rigorous clinical trials, extensive safety assessments, and long regulatory pathways, making development expensive and time-consuming.

Potential for Severe Adverse Reactions:

Despite their therapeutic potential, peanut allergy vaccines carry risks of allergic reactions during desensitization, which may deter widespread adoption.

Opportunity:

Expansion in Emerging Markets:

Rising allergy diagnostics awareness and improving healthcare infrastructure in Asia-Pacific and Latin America present untapped opportunities for vaccine developers.

Advancements in Biotechnology Platforms:

Breakthroughs in recombinant protein technology, DNA/RNA-based vaccines, and nanoparticle delivery systems are paving the way for more targeted and safer peanut allergy treatments.

Market by System Type Insights:

Based on system type, Injectable Vaccines dominated the market in 2023, driven by their clinical validation and ease of controlled administration. These vaccines are typically used in structured desensitization programs under physician supervision. However, the Oral Immunotherapy (OIT) segment is projected to grow fastest, owing to increasing acceptance of home-based treatments and improved patient compliance.

Market by End-use Insights:

Hospitals and Allergy Clinics accounted for the largest market share in 2023. These settings offer the infrastructure required for administering and monitoring allergy vaccines, particularly during the early stages of treatment. Meanwhile, the Home-based segment is expected to witness significant growth as regulatory authorities increasingly approve oral immunotherapies for at-home use.

Market by Regional Insights:

North America held the largest market share in 2023, driven by high awareness of food allergies, advanced healthcare infrastructure, and the presence of key industry players. Europe follows closely due to supportive reimbursement policies and increasing public health focus on allergy prevention. The Asia-Pacific region is poised to register the fastest growth during the forecast period, attributed to a rising number of allergy cases and evolving consumer awareness.

Competitive Scenario:

Leading companies in the Global Peanut Allergy Vaccine Market include:

Aimmune Therapeutics (Nestlé Health Science)

DBV Technologies

Camallergy Ltd.

Alladapt Immunotherapeutics

Aravax

Intrommune Therapeutics

These players are actively involved in clinical trials, strategic collaborations, and technology development. For instance:

In 2023, Nestlé’s Aimmune received FDA support for expanding Palforzia®, the first approved peanut allergy immunotherapy treatment.

DBV Technologies announced positive Phase 3 results for its Viaskin® patch therapy for pediatric patients in 2024.

Aravax, based in Australia, expanded its Phase 1/2 trials of PVX108 into the U.S. market in 2025.

Scope of Work – Global Peanut Allergy Vaccine Market

Report Metric Details

Market Size (2023) USD 360 million

Projected Market Size (2031) USD 1.06 billion

CAGR (2023–2031) 14.2%

Market Segments System Type, End-use, Region

Growth Drivers Rising peanut allergy prevalence, advances in immunotherapy, regulatory support

Opportunities Emerging markets, biotech innovations

Key Market Developments:

2023: Aimmune Therapeutics expanded distribution of Palforzia® into new global markets, including Canada and Germany.

2024: DBV Technologies announced successful completion of its pivotal Phase 3 trial for Viaskin Peanut.

2025: Aravax initiated a U.S. trial for its peptide-based immunotherapy, PVX108, showing promising tolerance profiles and efficacy.

FAQs:

What is the current market size of the Global Peanut Allergy Vaccine Market?

The market was valued at USD 360 million in 2023.

What is the major growth driver of the Global Peanut Allergy Vaccine Market?

The rising prevalence of peanut allergies and increasing investment in allergen immunotherapy are key growth drivers.

Which is the largest region during the forecast period in the Global Peanut Allergy Vaccine Market?

North America remains the largest region due to high allergy incidence rates and advanced healthcare systems.

Which segment accounted for the largest market share in the Global Peanut Allergy Vaccine Market?

The Injectable Vaccines segment held the largest share in 2023.

Who are the key market players in the Global Peanut Allergy Vaccine Market?

Key players include Aimmune Therapeutics, DBV Technologies, Aravax, Camallergy Ltd., and Alladapt Immunotherapeutics.